logo

Kala Pharmaceuticals, Inc. (KALA)



Trade KALA now with
  Date
  Headline
1/5/2018 7:06:01 AM Kala Reports Topline Results For Two Phase 3 Trials Of KPI-121 0.25% In Dry Eye Disease
1/5/2018 6:53:27 AM Kala Pharma Says FDA Accepts NDA For INVELTYS For Review
12/28/2017 4:26:12 AM Watch These 6 Biotech Stocks
12/22/2017 1:09:33 PM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $46 Price Target
12/5/2017 6:15:05 AM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $46 Price Target
11/30/2017 1:02:36 PM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $46 Price Target
11/13/2017 8:06:36 AM Kala Pharma Names Todd Bazemore COO
10/25/2017 8:09:33 AM Kala Submits NDA To FDA For INVELTYSTM (KPI-121 1%)
10/19/2017 2:10:08 PM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $46.00 Price Target
8/14/2017 6:24:50 AM Wedbush Initiates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $46 Price Target